Evotec (ETR:EVT) Stock Price Down 0.7% - Here's What Happened

Key Points

• Shares fell 0.7% to €4.12 (intraday low €4.06) with 452,587 shares traded, a drop of about 67% from the average session volume.
• Evotec trades below its 50‑day (€5.63) and 200‑day (€5.85) moving averages, has a market cap of $764.3M and a negative P/E of -4.46, while showing a debt‑to‑equity of 60.57 and healthy current/quick ratios (>2).
• Evotec is a drug discovery and development partner with numerous collaborations (including Sanofi, Bristol Myers Squibb, Bayer and Exscientia) and a strategic partnership with Dewpoint to advance biomolecular condensate‑targeted therapies.

Evotec SE (ETR:EVT - ) traded down 0.7% on Wednesday . The company traded as low as €4.06 and last traded at €4.12. 452,587 shares traded hands during trading, a decline of 67% from the average session volume of 1,360,000 shares. The stock had previously closed at €4.15.

Evotec Stock Performance

The company has a debt-to-equity ratio of 60.57, a current ratio of 2.12 and a quick ratio of 2.97. The company has a 50 day simple moving average of €5.63 and a 200-day simple moving average of €5.85. The stock has a market cap of $764.26 million, a P/E ratio of -4.46, a price-to-earnings-growth ratio of 0.98 and a beta of 1.12.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.